Former UFC heavyweight champion has been notified by the US Anti-Doping Agency of a failed out-of-competition medicine measure on 28 June
Brock Lesnar has been pennant for a potential anti-doping misdemeanour in the wake of his unanimous-decision succes over Mark Hunt at UFC 200.
The UFC problem a statement on Friday afternoon saying Lesnar and the advertisement had been notified by the US Anti-Doping Agency of a failed out-of-competition pharmaceutical measure on 28 June. Usada did not reveal the name of the substance Lesnar tested positive for in keeping with managerial policy.
A decorated amateur wrestler, Lesnar signed with the UFC in 2007 and defeated Randy Couture for the advertisings heavyweight championship the subsequent year. He drew two successful title defenses before losing to Cain Velasquez by first-round TKO, then announced his retirement from motley martial arts after a stoppage loss to Alistair Overeem in 2011.
Saturdays fight with Hunt was Lesnars firstly in five years old. The 38 -year-old South Dakota native payed a record $2.5 m pocketbook for the three-round places prevail, with all three judges handing down scores of 29 -2 8.
The UFC said Usada, the independent head of the organizations anti-doping program, received the testing results from the 28 June sample accumulation on Thursday evening after it was experimented at the Wada-accredited UCLA Olympic Analytical Laboratory.
The original headline bout of Saturdays card a light-footed heavyweight deed push between Jon Jones and Daniel Cormier was scrapped when Jones tested positive for a censored substance. Cormier instead fought Anderson Silva on the undercard, while the status of women bantamweight championship battle between Amanda Nunes and Miesha Tate was elevated to the main event.
The UFC 200 main event had to be scrapped three days before the happen because Jon Jones tested positive for banned elements in an out-of-competition research. Daniel Cormier fought Anderson Silva instead. Jones is also awaiting the USADA adjudication process.
Read more: www.theguardian.com